您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Ingenol 3,20-dibenzoate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Ingenol 3,20-dibenzoate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Ingenol 3,20-dibenzoate图片
规格:98%
分子量:556.65
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议

产品介绍
Ingenol3,20-dibenzoate是一种有效的蛋白激酶C(PKC)亚型选择性激动剂。Ingenol3,20-dibenzoate诱导nPKC-delta、-epsilon和-theta和PKC-mu从胞质部分选择性转移到颗粒组分,并通过从头合成大分子诱导形态上典型的凋亡(apoptosis)。Ingenol3,20-dibenzoate可促进NK细胞产生IFN-γ和脱颗粒,尤其是当NSCLC细胞刺激NK细胞时。
货号:ajcx32432
CAS:59086-90-7
分子式:C34H36O7
分子量:556.65
溶解度:N/A
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Ingenol 3,20-dibenzoate is a potent protein kinase C (PKC) isoform-selective agonist. Ingenol 3,20-dibenzoate induces selective translocation of nPKC-delta, -epsilon, and -theta and PKC-mu from the cytosolic fraction to the particulate fraction and induces morphologically typical apoptosis through de novo synthesis of macromolecules. Ingenol 3,20-dibenzoate increases the IFN-γ production and degranulation by NK cells, especially when NK cells are stimulated by NSCLC cells[1][2].

Ingenol 3,20-dibenzoate (0-10000 nM; 4 hours) enhanced NK cells (stimulated by A549 cells and H1299 cells) degranulation[2].Ingenol 3,20-dibenzoate (0.001-10 μg/ml) dose dependently promoted UT-7/EPO cell proliferation with an EC50 of 0.27 μg/ml (485 nM)[3].

Ingenol 3,20-dibenzoate (20 μg/mouse; i.p.; on days 3, 7, and 11) lessens the anemia induced by 5-fluorouracil in an in vivo mouse model[3]. Animal Model: Male C57BL/6 mice (8-12 weeks old)[3]

[1]. Asada A, et al. Induction of thymocyte apoptosis by Ca2+-independent protein kinase C (nPKC) activation and its regulation by calcineurin activation. J Biol Chem. 1998;273(43):28392-28398. [2]. Gong C, et al. Enhancement of NK cell-mediated lysis of non-small lung cancer cells by nPKC activator, ingenol 3,20 dibenzoate. Mol Immunol. 2017;83:23-32. [3]. Oh JG, et al. Biphasic Effects of Ingenol 3,20-Dibenzoate on the Erythropoietin Receptor: Synergism at Low Doses and Antagonism at High Doses. Mol Pharmacol. 2015;88(2):392-400.